Ipsen (IPN) H1 2025 earnings summary

Executive summary

• H1 2025 total sales grew 11.4% at constant exchange rates, with strong contributions from Rare Disease (+95.7%), Neuroscience (+9.7%), and Oncology (+6.4%).

• Core operating margin reached 36.0% of sales, reflecting operational efficiency and favorable product mix.

• Upgraded FY 2025 guidance: total sales growth expected to exceed 7% at constant exchange rates and core operating margin above 32%.

• Pipeline advanced with European approval for Cabometyx in neuroendocrine tumors, regulatory filing for tovorafenib in Europe, and initiation of Phase II trials for IPN10200 and LANT.

• Free cash flow increased 22.8% to €483 million, supporting a net cash position of €488 million at period end.

Financial highlights

• H1 2025 total sales: €1,820 million (+11.4% CER, +9.7% reported year-over-year).

• Core operating income: €656 million (+21.9%); core net profit: €508.3 million (+27.3%).

• IFRS operating income: €451.6 million (+42.1%); IFRS net profit: €335.5 million (+44.4%).

• Core EPS: €6.07 (+27.0%); IFRS EPS: €4.00 (+44.0%).

• Free cash flow: €483 million (+22.8% year-over-year); net cash position at €488 million at period end.

Outlook and guidance

• FY 2025 guidance upgraded: total sales growth expected to exceed 7% at constant exchange rates, core operating margin above 32%.

• Guidance factors in negative impact from potential increased generic competition for Somatuline and currency headwinds of about -2%.

• Excludes impact from potential late-stage business development transactions.

• Ongoing launches and strong uptake of new products, especially in Rare Disease, expected to support future growth.